全文获取类型
收费全文 | 115619篇 |
免费 | 7446篇 |
国内免费 | 933篇 |
专业分类
耳鼻咽喉 | 1266篇 |
儿科学 | 3328篇 |
妇产科学 | 2804篇 |
基础医学 | 14793篇 |
口腔科学 | 2718篇 |
临床医学 | 9165篇 |
内科学 | 26722篇 |
皮肤病学 | 2259篇 |
神经病学 | 10683篇 |
特种医学 | 4546篇 |
外国民族医学 | 23篇 |
外科学 | 17710篇 |
综合类 | 1686篇 |
一般理论 | 53篇 |
预防医学 | 6081篇 |
眼科学 | 1964篇 |
药学 | 9012篇 |
3篇 | |
中国医学 | 542篇 |
肿瘤学 | 8640篇 |
出版年
2023年 | 584篇 |
2022年 | 563篇 |
2021年 | 2258篇 |
2020年 | 1602篇 |
2019年 | 2283篇 |
2018年 | 2831篇 |
2017年 | 2124篇 |
2016年 | 2306篇 |
2015年 | 2591篇 |
2014年 | 3436篇 |
2013年 | 4808篇 |
2012年 | 6686篇 |
2011年 | 6804篇 |
2010年 | 4331篇 |
2009年 | 3852篇 |
2008年 | 6009篇 |
2007年 | 6139篇 |
2006年 | 5836篇 |
2005年 | 5620篇 |
2004年 | 5866篇 |
2003年 | 5480篇 |
2002年 | 5445篇 |
2001年 | 3787篇 |
2000年 | 3725篇 |
1999年 | 3027篇 |
1998年 | 1144篇 |
1997年 | 906篇 |
1996年 | 824篇 |
1995年 | 894篇 |
1994年 | 789篇 |
1993年 | 769篇 |
1992年 | 1848篇 |
1991年 | 1795篇 |
1990年 | 1548篇 |
1989年 | 1474篇 |
1988年 | 1353篇 |
1987年 | 1204篇 |
1986年 | 1202篇 |
1985年 | 1070篇 |
1984年 | 794篇 |
1983年 | 721篇 |
1982年 | 488篇 |
1981年 | 404篇 |
1979年 | 577篇 |
1978年 | 423篇 |
1975年 | 436篇 |
1974年 | 492篇 |
1973年 | 461篇 |
1972年 | 425篇 |
1971年 | 397篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
Cifuentes-Faura Javier Di Francesco Renaud 《The European journal of health economics》2022,23(4):559-563
The European Journal of Health Economics - 相似文献
3.
Olivari Davide De Giorgio Daria Staszewsky Lidia Irene Fumagalli Francesca Boccardo Antonio Novelli Deborah Manfredi Martina Babini Giovanni Luciani Anita Ruggeri Laura Magliocca Aurora Zani Davide Danilo Masson Serge Belloli Angelo Pravettoni Davide Maiocchi Giuseppe Latini Roberto Ristagno Giuseppe 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(4):727-738
Cardiovascular Drugs and Therapy - Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine model of decompensated... 相似文献
4.
5.
Davide Fiore Bavaro Flavia Balena Luigi Ronga Fabio Signorile Federica Romanelli Stefania Stolfa Eleonora Sparapano Carmela De Carlo Adriana Mosca Laura Monno Gioacchino Angarano Annalisa Saracino 《Journal de Mycologie Médicale》2022,32(1):101206
An increased number of patients is at risk of Candida spp. bloodstream infection (CBSI) in modern medicine. Moreover, the rising of antifungal resistance (AR) was recently reported. All consecutive CBSI occurred in our Hospital (consisting of 1,370 beds) between 2015 and 2018, were reviewed. For each case, Candida species, AR pattern, ward involved and demographic data of patients were recorded. Overall, 304 episodes of CBSI occurred, with a median (q1:first-,q3:third quartile) of 77 (71-82) CBSI/year. Over the years, a significant increase of CBSI due to C. albicans compared to non-albicans strains was recorded in medical wards (from 65% to 71%, p=0.030), while this ratio remained stable in others. An increase of resistant strains to multiple antifungals such as C. guillermondii was noticed in recent years (from 0% to 9.8%, p=0.008). Additionally, from 2015 to 2018 an increase in fluconazole-resistance was recorded in our Hospital (from 7.4% to 17.4%, p=0.025) and a slight increase in voriconazole-resistance (from 0% to 7% in 2018, p=0.161) was observed, while resistance to echinocandin and amphotericin B remained firmly below 2%.This study suggests a rapid spread of antifungal resistance in our Hospital; therefore, an appropriate antifungal stewardship programs is urgently warranted. 相似文献
6.
7.
Aldo Cannata Silvia Cantoni Antonio Sciortino Giuseppe Bruschi Claudio Francesco Russo 《Journal of the American College of Cardiology》2021,77(18):2323-2334
Mechanical intravascular hemolysis is frequently observed following procedures on heart valves and uncommonly observed in native valvular disease. In most cases, its severity is mild. Nevertheless, it can be clinically significant and even life threatening, requiring multiple blood transfusions and renal replacement therapy. This paper reviews the current knowledge on mechanical intravascular hemolysis in valvular disease, before and after correction, focusing on pathophysiology, approach to diagnosis, and impact of other hematological conditions on the resultant anemia. The importance of a multidisciplinary management is underscored. Laboratory data are provided about subclinical hemolysis that is commonly observed following the implantation of surgical and transcatheter valve prostheses and devices. Finally, clinical scenarios are reviewed and current medical and surgical treatments are discussed, including alternative options for inoperable patients. 相似文献
8.
9.
YIN Yue Qi LU Jing ZHOU Ying SHI Ling En YUAN De Fu CHEN Jian Shuang XUAN Yan HU Hai Yang ZHANG Zhi XU Xiao Qin FU Geng Feng WANG Bei 《Biomedical and environmental sciences : BES》2021,34(5):400-403,中插4
Integrase strand transfer inhibitors (InSTIs) have been widely used in recent years because of their high genetic barrier to resistance. The World Health Organization (WHO) has recommended dolutegravir (DTG)-containing regimens as the preferred first- and second-line antiretroviral therapy (ART) regimens for people living with human immunodeficiency virus (HIV)[1]. During the long-term treatment process, the appearance of drug resistance mutations to InSTIs is inevitable. A meta-analysis has shown that the resistance rate among InSTI treatment-experienced patients is 3.9% (Raltegravir, RAL), 1.2% (Elvitegravir, EVG), and 0.1% (DTG)[2]. However, resistance to InSTIs has not been reported in treatment-naive populations. 相似文献
10.
Alessandro Mandurino-Mirizzi Vilma Kajana Stefano Cornara Alberto Somaschini Andrea Demarchi Marco Galazzi Gabriele Crimi Marco Ferlini Rita Camporotondo Massimiliano Gnecchi Maurizio Ferrario Luigi Oltrona-Visconti Gaetano M. De Ferrari 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(7):2140-2143
BackgroundContrast associated-acute kidney injury (CA-AKI) has been associated with adverse outcomes after ST-segment elevation myocardial infarction (STEMI). However, early markers of CA-AKI are still needed to improve risk stratification. We investigated the association between elevated serum uric acid (eSUA) and CA-AKI in patients with STEMI treated with primary percutaneous coronary intervention (pPCI).Methods and resultsSerum creatinine (Scr) was measured at admission and 24, 48 and 72 h after pPCI. CA-AKI was defined as an increase of 25% (CA-AKI 25%) or 0.5 mg/dl (CA-AKI 0.5) of Scr level above the baseline after 48 h following contrast administration. Multivariable analyses to investigate CA-AKI predictors were performed by binary logistic regression and multivariable backward logistic regression model.In the 3023 patients considered, CA-AKI was more frequent among patients with eSUA as compared with patients with normal SUA levels, considering both CA-AKI definitions (CA-AKI25%: 20.8% vs 16.2%, p < 0.012; CA-AKI 0.5: 10.1% vs 5.8%, p < 0.001). The association between eSUA and CA-AKI was confirmed at multivariable analyses (CA-AKI 25%: odd ratio 1.32, 95% CI 1.03–1.69, p = 0.027; CA-AKI 0.5: odd ratio 1.76, 95% CI 1.11–2.79, p = 0.016).ConclusionElevated serum uric acid is associated with CA-AKI after reperfusion in patients with STEMI treated with pPCI. 相似文献